Barbara Balser

1.2k total citations · 1 hit paper
14 papers, 792 citations indexed

About

Barbara Balser is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Barbara Balser has authored 14 papers receiving a total of 792 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Immunology. Recurrent topics in Barbara Balser's work include Histone Deacetylase Inhibitors Research (10 papers), Peptidase Inhibition and Analysis (6 papers) and T-cell and Retrovirus Studies (4 papers). Barbara Balser is often cited by papers focused on Histone Deacetylase Inhibitors Research (10 papers), Peptidase Inhibition and Analysis (6 papers) and T-cell and Retrovirus Studies (4 papers). Barbara Balser collaborates with scholars based in United States, Australia and France. Barbara Balser's co-authors include Sarah McCue Horwitz, Bertrand Coiffier, H. Miles Prince, Lubomir Sokol, Barbara Pro, Jean Nichols, Francine M. Foss, Andrei R. Shustov, Matthew Greenwood and Dolores Caballero and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Barbara Balser

14 papers receiving 774 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

2012 485 citations Bertrand Coiffier, Barbara Pro et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Barbara Balser

Since Specialization

Citations

This map shows the geographic impact of Barbara Balser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Balser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Balser more than expected).

Fields of papers citing papers by Barbara Balser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Balser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Balser. The network helps show where Barbara Balser may publish in the future.

Co-authorship network of co-authors of Barbara Balser

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Balser. A scholar is included among the top collaborators of Barbara Balser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Balser. Barbara Balser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections 2020 ·Journal of Medical Microbiology ·Stephanie Noviello, G. Ralph Corey, Thomas L Holland, Thomas P. Lodise, William O’Riordan, Mark H. Wilcox, Thomas M. File, Matthew Dryden, Barbara Balser, (unknown), Antoni Torres, David B. Huang	3
2	A Pooled Analysis of the Safety and Efficacy of Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Intravenous Drug Use: Phase 3 REVIVE Studies 2019 ·Clinical Therapeutics ·David B. Huang, Stephanie Noviello, Barbara Balser, (unknown), G. Ralph Corey	7
3	Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections 2018 ·International Journal of Antimicrobial Agents ·David B. Huang, G. Ralph Corey, Thomas L Holland, Thomas P. Lodise, William O’Riordan, Mark H. Wilcox, Thomas M. File, Matthew Dryden, Barbara Balser, (unknown), Antoní Torres	14
4	Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials 2017 ·Leukemia & lymphoma ·Andrei R. Shustov, Bertrand Coiffier, Sarah McCue Horwitz, Lubomir Sokol, Barbara Pro, Julie Wolfson, Barbara Balser, (unknown), Leslie Popplewell, H. Miles Prince, Steven L. Allen, Richard Piekarz, Susan E. Bates	14
5	Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial 2016 ·Journal of Hematology & Oncology ·Francine M. Foss, Sarah McCue Horwitz, Barbara Pro, H. Miles Prince, Lubomir Sokol, Barbara Balser, Julie Wolfson, Bertrand Coiffier	38
6	Utility of18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma 2015 ·Annals of Oncology ·Sarah McCue Horwitz, Bertrand Coiffier, Francine M. Foss, H. Miles Prince, Lubomir Sokol, Matthew Greenwood, Dolores Caballero, Franck Morschhauser, Lauren Pinter‐Brown, Swaminathan P. Iyer, Andrei R. Shustov, (unknown), John Balser, Barbara Balser, Barbara Pro	12
7	Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin 2015 ·Cancer Medicine ·Philip T. Sager, Barbara Balser, Julie Wolfson, Jean Nichols, Richard Pilot, Suzanne F. Jones, Howard A. Burris	31
8	Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma 2014 ·Biomarker Research ·Francine M. Foss, Bertrand Coiffier, Sarah McCue Horwitz, Barbara Pro, H. Miles Prince, Lubomir Sokol, Matthew Greenwood, Adam Lerner, Dolores Caballero, Eugeniusz Baran, Ellen Kim, Jean Nichols, Barbara Balser, Julie Wolfson, Sean Whittaker	24
9	Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses 2014 ·Journal of Hematology & Oncology ·Bertrand Coiffier, Barbara Pro, H. Miles Prince, Francine M. Foss, Lubomir Sokol, Matthew Greenwood, Dolores Caballero, Franck Morschhauser, Martin Wilhelm, Lauren Pinter‐Brown, Swaminathan P. Iyer, Andrei R. Shustov, Tina Nielsen, Jean Nichols, Julie Wolfson, Barbara Balser, Sarah McCue Horwitz	147
10	Romidepsin Induces Durable Responses in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) 2014 ·Blood ·Barbara Pro, Steven M. Horwitz, H. Miles Prince, Francine M. Foss, Lubomir Sokol, Matthew Greenwood, Dolores Caballero, Franck Morschhauser, Martin Wilhelm, Lauren Pinter‐Brown, Swaminathan P. Iyer, Andrei R. Shustov, Julie Wolfson, Barbara Balser, Bertrand Coiffier	3
11	Romidepsin Is Effective and Well-Tolerated In Patients ≥ 60 Years Old With Relapsed Or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials 2013 ·Blood ·Andrei R. Shustov, Bertrand Coiffier, Steven M. Horwitz, Lubomir Sokol, Barbara Pro, Tina Nielsen, Julie Wolfson, Barbara Balser, (unknown), Leslie Popplewell, Miles Prince, Steven L. Allen, Richard Piekarz, Susan E. Bates	4
12	Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy breakdown → 2012 ·Journal of Clinical Oncology ·Bertrand Coiffier, Barbara Pro, H. Miles Prince, Francine M. Foss, Lubomir Sokol, Matthew Greenwood, Dolores Caballero, Peter Borchmann, Franck Morschhauser, Martin Wilhelm, Lauren Pinter‐Brown, Swaminathan P. Iyer, Andrei R. Shustov, Jean Nichols, Susan Carroll, John Balser, Barbara Balser, Sarah McCue Horwitz	485
13	Romidepsin Induces Durable Responses in Patients with Peripheral T-Cell Lymphoma: GPI-06–0002 Study Update 2012 ·Blood ·Bertrand Coiffier, Barbara Pro, Miles Prince, Francine M. Foss, Lubomir Sokol, Matthew Greenwood, Dolores Caballero, Franck Morschhauser, Martin Wilhelm, Lauren Pinter‐Brown, Swaminathan P. Iyer, Andrei R. Shustov, Tina Nielsen, Jean Nichols, Julie Wolfson, Barbara Balser, Steven M. Horwitz	3
14	Exposure-QTc Response Analysis of Class 1 Selective Histone Deacetylase Inhibitor Romidepsin 2011 ·Blood ·Christopher Godfrey, Christopher H. Cabell, Barbara Balser, Julie Wolfson, Jean Nichols, Howard A. Burris	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact